News | August 01, 2025
Jubilant Ingrevia Q1 FY26 YoY net profit jumps 54% to Rs. 75 Cr
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
The Genexus platform enables Next-Generation Sequencing with significantly faster turnaround times
Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit
Aman holds a bachelor’s degree in economics from Boston University and an MBA from Columbia University, New York
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
Kushwaha previously served as Chief Digital & Information Officer at Jubilant Ingrevia Limited
This achievement is part of the population-based initiative for screening, prevention, and management of Non-Communicable Diseases
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
This GMP certification for our sterile drug product manufacturing facility, Goa Plant II is a testament to our relentless efforts to supply quality and affordable medicines across geographies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
